GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » ROC (Joel Greenblatt) %

Cyfuse Biomedical KK (TSE:4892) ROC (Joel Greenblatt) % : 0.00% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Cyfuse Biomedical KK's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Cyfuse Biomedical KK's ROC (Joel Greenblatt) % or its related term are showing as below:

TSE:4892' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -829.53   Med: -271.34   Max: 247.05
Current: -302.26

During the past 5 years, Cyfuse Biomedical KK's highest ROC (Joel Greenblatt) % was 247.05%. The lowest was -829.53%. And the median was -271.34%.

TSE:4892's ROC (Joel Greenblatt) % is ranked worse than
91.33% of 992 companies
in the Drug Manufacturers industry
Industry Median: 10.005 vs TSE:4892: -302.26

Cyfuse Biomedical KK's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Cyfuse Biomedical KK ROC (Joel Greenblatt) % Historical Data

The historical data trend for Cyfuse Biomedical KK's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK ROC (Joel Greenblatt) % Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
ROC (Joel Greenblatt) %
-829.53 247.05 -271.34 -246.61 -393.54

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -286.39 -91.45 -403.62 -403.31 -

Competitive Comparison of Cyfuse Biomedical KK's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyfuse Biomedical KK's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's ROC (Joel Greenblatt) % falls into.


;
;

Cyfuse Biomedical KK ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.87 + 49.457 + 65.532) - (45.041 + 0 + 64.676)
=9.1420000000001

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(20.938 + 55.586 + 67.97) - (75.185 + 0 + 47.61)
=21.699

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Cyfuse Biomedical KK for the quarter that ended in Dec. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (210.751 + max(9.1420000000001, 0)) + (192.499 + max(21.699, 0)) )/ 2 )
=0/( ( 219.893 + 214.198 )/ 2 )
=0/217.0455
=0.00 %

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyfuse Biomedical KK  (TSE:4892) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Cyfuse Biomedical KK ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyfuse Biomedical KK Business Description

Traded in Other Exchanges
N/A
Address
3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK Headlines

No Headlines